Table 3. Comparison of preoperative demographic, ultrasonographic parameters, FNAC and sequence results of the groups.
| pLN 0 | pLN 1 | p | |
| Age | 43.9 ±12.9 | 42 ±13.8 | 0.583* |
| Sex | 0.005 | ||
| Female | 26 (89.7%) | 19 (55.9%) | |
| Male | 3 (10.3%) | 15 (44.1%) | |
| Ultrasonographic parameters | |||
| Number of nodule | 2 (1-3) | 3 (2-3) | 0.132ⱡ |
| Nodule size (mm) | 13 (7.5-18) | 18 (13.8-22.3) | 0.004ⱡ |
| Echogenicity | 0.154† | ||
| Hypoechogenous | 20 (69%) | 16 (47.1%) | |
| Isoechogenous | 2 (6.9%) | 7 (20.6%) | |
| Mixed | 7 (24.1%) | 11 (32.4%) | |
| Cystic-solid construction | 0.861† | ||
| Cystic | 2 (6.9%) | 2 (5.9%) | |
| Solid | 17 (58.6%) | 18 (52.9%) | |
| Mixed | 10 (34.5%) | 14 (41.2%) | |
| Microcalcification | 0.009† | ||
| (-) | 18 (62.1%) | 10 (29.4%) | |
| (+) | 11 (37.9%) | 24 (70.6%) | |
| Blood supply of nodule | 0.268† | ||
| (-) | 13 (44.8%) | 20 (58.8%) | |
| (+) | 16 (55.2%) | 14 (41.2%) | |
| Border regularity | 0.251† | ||
| Regular | 17 (58.6%) | 15 (44.1%) | |
| Irregular | 12 (41.4%) | 19 (55.9%) | |
| LN metastasis | 0.097† | ||
| (-) | 15 (51.8%) | 11 (32.3%) | |
| (+) | 14 (48.2%) | 23 (67.7%) | |
| FNAC results | |||
| Nuclear elongation | 0.681† | ||
| (-) | 8 (27.6%) | 11 (32.4%) | |
| (+) | 21 (72.4%) | 23 (67.6%) | |
| Discohesive cell | 0.859† | ||
| (-) | 13 (44.8%) | 16 (47.1%) | |
| (+) | 16 (55.2%) | 18 (52.9%) | |
| Nuclear notching | 0.758† | ||
| (-) | 10 (34.5%) | 13 (38.2%) | |
| (+) | 19 (65.5%) | 21 (61.8%) | |
| Irregular nucleus | 0.231† | ||
| (-) | 7 (24.1%) | 13 (38.2%) | |
| (+) | 22 (75.9%) | 21 (61.8%) | |
| Cytoplasmic clarification | 0.080† | ||
| (-) | 9 (31%) | 18 (52.9%) | |
| (+) | 20 (69%) | 16 (47.1%) | |
| Intranuclear inclusions | 0.512† | ||
| (-) | 8 (27.6%) | 12 (35.3%) | |
| (+) | 21 (72.4%) | 22 (64.7%) | |
| Oncocytic morphology | 0.233† | ||
| (-) | 11 (37.9%) | 18 (52.9%) | |
| (+) | 18 (62.1%) | 16 (47.1%) | |
| Multinuclear histiocytic giant cell | 0.572† | ||
| (-) | 15 (51.7%) | 20 (58.8%) | |
| (+) | 14 (48.3%) | 14 (41.2%) | |
| BRAFV600E | 0.005† | ||
| (-) | 25 (86.2%) | 18 (52.9%) | |
| (+) | 4 (13.8%) | 16 (47.1%) | |
| *: mean ± SD and Student’s t test †: number and Fisher’s exact test or Pearson chi square test ⱡ: median (IQR) and Mann Whitney U test LN: Lymph node, pLN0: Patients with lymph node involvement, pLN1: Patients with lymph node involvement. | |||